[Ceftizoxime concentration in blood, muscle, and kidney tissue].
The pharmacokinetic properties of ceftizoxime, a new beta-lactamase-resistant cephalosporin, were investigated in 27 patients following perioperative antimicrobial prophylaxis. 2 g of ceftizoxime were injected before surgery and the concentrations measured in serum, muscle and renal tissue over a period of 30 min to 7 h. The pharmacokinetic data indicated high and long-lasting concentrations of ceftizoxime, especially in the renal tissue; this makes the drug ideal for the treatment of complicated urinary tract infections with obstruction and involvement of the renal tissue, provided the bacteria present are sensitive. The administration of 2 g i. v. every 12 h should be sufficient. In view of the high and long-lasting concentrations, it should be possible to treat uncomplicated urinary tract infections with a single dose of 2 g every 24 h. However, Enterococci, Bacteroides and Pseudomonas aeruginosa are not sufficiently sensitive to ceftizoxime and a combination with an aminoglycoside is thus indicated in the treatment of high-risk patients in the absence of bacteriological tests.
D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D015296:Ceftizoxime; D005260:Female; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000378:metabolism*; D011292:Premedication
D015296:Ceftizoxime; D002439:Cefotaxime
Konzentrationen von Ceftizoxim in Serum, Muskel- und Nierengewebe.